{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:02:08Z","timestamp":1791158528574,"version":"4.1.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,15]]},"DOI":"10.2169\/internalmedicine.0383-17","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T22:26:43Z","timestamp":1520548003000},"page":"2377-2382","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary Adenocarcinoma, Harboring Both an &lt;i&gt;EGFR&lt;\/i&gt; Mutation and &lt;i&gt;ALK&lt;\/i&gt; Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib"],"prefix":"10.2169","volume":"57","author":[{"given":"Akira","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"},{"name":"Department of Respiratory Medicine, Graduated School of Medicine, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhisa","family":"Tamura","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kusaka","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shimada","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hirose","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kitani","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hebisawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[{"name":"Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.","DOI":"10.1093\/jnci\/dji055"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11: 190-198, 2006.","DOI":"10.1007\/s10147-006-0583-4"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming <i>EML4<\/i>-<i>ALK<\/i> fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.","DOI":"10.1038\/nature05945"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Koivunen JP, Merme C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283, 2008.","DOI":"10.1158\/1078-0432.CCR-08-0168"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Inamura K, Takeuchi K, Togashi Y, et al. <i>EML4<\/i>-<i>ALK<\/i> lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology 22: 508-515, 2009.","DOI":"10.1038\/modpathol.2009.2"},{"key":"6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.lungcan.2012.04.012","volume":"77","author":"JK Lee","year":"2012","unstructured":"6. Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring <i>EGFR<\/i> mutation and <i>ALK<\/i> translocation. Lung Cancer 77: 460-463, 2012.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yang JJ, Zhang XC, Su J, et al. Lung cancers with concomitant <i>EGFR<\/i> mutations and <i>ALK<\/i> rearrangements: Diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 20: 1383-1392, 2014.","DOI":"10.1158\/1078-0432.CCR-13-0699"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW. Non-small cell lung cancer with concomitant <i>EGFR<\/i>, <i>KRAS<\/i>, and <i>ALK<\/i> mutation: clinicopathologic features of 12 cases. J Pathol Transl Med 50: 197-203, 2016.","DOI":"10.4132\/jptm.2016.03.09"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhao N, Zheng SY, Yang JJ, et al. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review. Clin Lung Cancer 16: e5-e9, 2015.","DOI":"10.1016\/j.cllc.2014.11.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.","DOI":"10.1056\/NEJMoa0810699"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced <i>EGFR<\/i> mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced <i>ALK<\/i>-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.","DOI":"10.1056\/NEJMoa1214886"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in <i>ALK<\/i>-positive lung cancer. N Engl J Med 371: 2167-2177, 2014.","DOI":"10.1056\/NEJMoa1408440"},{"key":"15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"15. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with <i>ALK<\/i>-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390: 29-39, 2017.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor <i>EML4<\/i>-<i>ALK<\/i>. J Clin Oncol 27: 4247-4253, 2009.","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051-6060, 2011.","DOI":"10.1158\/0008-5472.CAN-11-1340"},{"key":"18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2014.09.011","volume":"86","author":"L Baldi","year":"2014","unstructured":"18. Baldi L, Mengoli MC, Bisagni A, Banzi MC, Boni C, Rossi G. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer 86: 291-295, 2014.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cai W, Lin D, Wu C, et al. Intratumoral heterogeneity of <i>ALK<\/i>-rearranged and <i>ALK<\/i>\/<i>EGFR<\/i> coaltered lung adenocarcinoma. J Clin Oncol 33: 3701-3709, 2015.","DOI":"10.1200\/JCO.2014.58.8293"},{"key":"20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2407-13-262","volume":"13","author":"A Miyanaga","year":"2013","unstructured":"20. Miyanaga A, Shimizu K, Noro R, et al. Activity of EGFR-tyrosine kinase and ALK inhibitors for <i>EML4<\/i>-<i>ALK<\/i>-rearranged non-small-cell lung cancer harbored coexisting <i>EGFR<\/i> mutation. BMC Cancer 13: 262, 2013.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2013.05.003","volume":"81","author":"X Chen","year":"2013","unstructured":"21. Chen X, Zhang J, Hu Q, Li X, Zhou C. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer 81: 308-310, 2013.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chiari R, Duranti S, Ludovini V, et al. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and <i>EML4<\/i>-<i>ALK<\/i> fusion gene. J Clin Oncol 32: e30-e32, 2014.","DOI":"10.1200\/JCO.2012.47.7141"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Won JK, Keam B, Koh J, et al. Concomitant <i>ALK<\/i> translocation and <i>EGFR<\/i> mutation in lung cancer: A comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol 26: 348-354, 2015.","DOI":"10.1093\/annonc\/mdu530"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sahnane N, Frattini M, Bernasconi B, et al. <i>EGFR<\/i> and <i>KRAS<\/i> mutations in <i>ALK<\/i>-positive lung adenocarcinomas: biological and clinical effect. Clin Lung Cancer 17: 56-61, 2016.","DOI":"10.1016\/j.cllc.2015.08.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory <i>ALK<\/i>-rearranged non-small-cell lung cancer: a Phase II Global Study. J Clin Oncol 34: 661-668, 2016.","DOI":"10.1200\/JCO.2015.63.9443"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in <i>ALK<\/i>-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17: 234-242, 2016.","DOI":"10.1016\/S1470-2045(15)00488-X"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with <i>ALK<\/i>-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590-598, 2013.","DOI":"10.1016\/S1470-2045(13)70142-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ikeda S, Yoshioka H, Arita M, et al. Interstitial lung disease induced by alectinib (CH5424802\/RO5424802). Jpn J Clin Oncol 45: 221-224, 2015.","DOI":"10.1093\/jjco\/hyu183"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yamamoto Y, Okamoto I, Otsubo K, et al. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. Invest New Drugs 33: 1148-1150, 2015.","DOI":"10.1007\/s10637-015-0284-9"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Chino H, Sekine A, Kitamura H, Kato T, Ogura T. Successful treatment with alectinib after crizotinib-induced interstitial lung disease. Lung Cancer 90: 610-613, 2015.","DOI":"10.1016\/j.lungcan.2015.09.019"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0383-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T04:48:58Z","timestamp":1534567738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/16\/57_0383-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0383-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]}}}